Emerging evidence shows that standard atazanavir (ATV) dosages are associated with considerable interindividual variability in plasma drug concentrations. Given the potential impact of ATV exposure on clinical outcome, in this retrospective study we sought to assess demographic and clinical factors influencing ATV plasma concentrations in a large cohort of HIV-infected patients.
Methods
HIV-infected patients treated with ATV for at least 3 months and with at least one assessment of ATV trough concentrations were enrolled. Blood trough samples were collected from all patients immediately before the next drug intake. Plasma ATV and ritonavir concentrations were quantified by a validated chromatographic method coupled with tandem mass spectrometric detection. Univariate and multivariate regression analyses were performed using ATV plasma concentrations as the dependent variable, with demographic and clinical characteristics as the independent ones.
Results
A total of 273 HIV-infected adult patients were included in the present study. Factors significantly associated with increased ATV concentrations by univariate analysis were ATV dosage, number of concomitant drugs, ritonavir or statin use. However, with multivariate regression analysis, the only factors independently and significantly associated with ATV concentrations were ritonavir use (r=0.291, P<0.0001) and concomitant rosuvastatin therapy (r=0.315, P<0.0001).
Conclusions
We found that patients on ATV/ritonavir given rosuvastatin concomitantly have ATV concentrations that exceed the upper therapeutic threshold of 800 ng/ml known to be associated with a high risk of experiencing ATV-related side effects. In agreement with previous findings we confirmed the lack of association between other demographic and clinical characteristics such as age, gender, body weight and ATV exposure.
References
1.
Le TiecC., BarrailA., GoujardC., TaburetA.M.Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.Clin Pharmacokinet2005; 44: 1035–1050.
2.
SolasC., GagnieuM.C., RavauxI.Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.Ther Drug Monit2008; 30: 670–673.
3.
Gonzalez de RequenaD., BonoraS., CantaF.Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range.12th Conference on Retroviruses and Opportunistic Infections. 22–25 February 2005, Boston, MA, USA. Abstract 646.
4.
SmithD.E., JeganathanS., RayJ.Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.HIV Clin Trials2006; 7: 34–38.
5.
CleijsenR.M., van de EndeM.E., KroonF.P.Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.J Antimicrob Chemother2007; 60: 897–900.
6.
GervasoniC., MeravigliaP., FerrarisS.Therapeutic atazanavir monitoring in the routine clinical practice: correlation between drug dosage, atazanavir concentrations and patients’ outcome.14th European AIDS Conferences. 16–19 October 2013, Brussels, Belgium. Abstract PE10/12.
7.
FayetA., BéguinA., ZanolariB.A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine.J Chromatogr B Analyt Technol Biomed Life Sci2009; 877: 1057–1069.
8.
ChauvinB., DrouotS., Barrail-TranA., TaburetA.M.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Clin Pharmacokinet2013; 52: 815–831.
9.
BustiA.J., BainA.M., HallR.G.IIEffects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.J Cardiovasc Pharmacol2008; 51: 605–610.
10.
LuzA.J., PoetaJ., LindenR., AntunesM.V., CaminhaL.I., SprinzE.Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load.Braz J Infect Dis2013; 17: 657–660.
11.
CattaneoD., BaldelliS., CastoldiS., CharbeN., CozziV., ClementiE.Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint.AIDS2014; 28: 2477–2480.
